In response to the competitive threat from Chinese firms operating at a different speed and cost, Pfizer's CEO states the only viable path forward is a radical transformation through technology, specifically citing AI. The goal is to fundamentally change processes to match the new competitive landscape.
Albert Bourla explains his divestiture of consumer healthcare by arguing that a corporation's role is not to hedge risk—that's for investors. Instead, companies must cultivate a focused culture to become exceptionally good in a few core areas, which for Pfizer is innovative science.
After a major internal scientific setback in the obesity space, Pfizer acquired a company with a promising drug. This strategy wasn't just about buying a product, but acquiring a missing scientific asset to plug into its existing world-class commercial and manufacturing infrastructure, thereby capitalizing on its established strengths.
Albert Bourla identifies Chinese pharmaceutical companies as a paradigm-shifting threat, not an incremental one. He quantifies their advantage as operating with "half the cost and three times the speed," demanding a fundamental transformation of Western pharma companies within five years to remain competitive.